Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of IMB-1018972 in healthy volunteers
NL-OMON48517Phase 1Active, not recruiting
- Sponsor
- Imbria Pharmaceuticals
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in angina pectoris, coronary arteriosclerosis and heart failure (HF) comparing IMB-1018972, Placebo and Trimetazidine (3 arms). Primary endpoint: Safety and tolerability of IMB-1018972 and trimetazidine. Started Feb 2019; status: active, not recruiting.
02
Drugs
ninerafaxstattrimetazidine
03
Conditions
angina pectoriscoronary arteriosclerosisheart failure (HF)
Beyond the preview
Go deeper on NL-OMON48517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48517.